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ABSTRACT
Determination of the levels of endotoxins in injectable products has always been 
one of the concerns of regulatory authorities and manufacturers. Since a number of 
pharmaceuticals interfere with the LAL test to some degree, overcoming the inhibition 
or enhancement properties of a product is required as part of the validation of the LAL 
test for use in the final release testing of parenteral products. In this study, interference 
profile of Heparin injection in quantitative chromogenic LAL test was evaluated and the 
method of overcoming was investigated and validated. The results indicate that dilution 
as the most widely used technique for overcoming interference could not eliminate LAL 
interference in the aforementioned medicinal product. The inhibitory nature of heparin 
occurs due to its anticoagulant properties and can be overcome by using divalent cations 
such as magnesium. Three concentrations of magnesium chloride were evaluated for 
elimination of heparin’s inhibitory effect. All three concentrations studied (5, 10 and 
25 mM) could effectively eliminate the inhibitory effects of heparin. Hence, one-way 
analysis of variance was used to determine statistically significant differences between 
these three concentrations.  The results of ANOVA statistical method showed the optimal 
recovery of spiked endotoxin was at a concentration of 10 mM of magnesium chloride. 
In consequence, chromogenic LAL test using 10 mM of magnesium chloride as diluent 
could be a validated method of choice for heparin LAL assay.
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Introduction
Bacterial endotoxins and pyrogens are one of the most 
important contaminants associated with injectable 
pharmaceuticals. Currently the most commonly used 
test for determination of  endotoxin level is Limulus 
Amebocyte Lysate (LAL) assay (Chalupniak et al., 2014). 
The LAL method is based on an endotoxin-induced 
coagulation reaction which offers a compendially-
approved sensitive and selective test to determine 
endotoxins (European Directorate for the Quality 
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of Medicines, 2013; United States Pharmacopeial 
Convention, 2014). However, the main concern associated 
with this method is the interaction of the LAL method 
with some substances tested for endotoxins, including 
metals, amino acids, antibiotics and enzymes which 
inhibit or enhance the coagulation reaction of LAL (Yuu 
et al., 2011). LAL (Enzyme cascade) and endotoxin are 
the major causes of bacterial endotoxin testing (BET) 
interference. LAL interference could be a result of non-
neutral pH, ionic strength, chelating of divalent cations, 
serine protease inhibitors, solvents and beta glucans. 
Endotoxin interference is related to aggregation and 
adsorption phenomena (Cooper et al., 1997).
Prior to LAL testing of any product, it has to be screened 
for interference (both inhibition and enhancement). 
Should interference exist then, as an integral part of the 
validation process for the use of LAL in the final release 
testing of injectable and medical devices, overcoming the 
inhibition or enhancement of the product is required by 
regulatory bodies  (Food and Drug Administration, 1992). 
Three types of LAL endotoxin testing methods namely 
the gel-clot, the chromogenic and the turbidimetric 
methods, have been approved by the United States 
Pharmacopeia and European Pharmacopoeia for the 
evaluation of injectable drugs, medical devices, and 
pharmaceutical raw materials (Joiner et al., 2002). Among 
these methods, the kinetic chromogenic assay is less 
affected by the inhibitory effect of those products which 
may interfere with the clotting mechanism in turbidimetric 
and gel clot assays (Lonza, 2012a).
The object of the present study was to investigate the 
suitability of the kinetic chromogenic LAL assay for the 
determination of endotoxin levels in heparin injections. 
Hence, the interference pattern of heparin was assessed 
and the way to eliminate the interference was evaluated 
and optimized. The method was then validated to optimize 
the quality control testing required for the final release 
testing of the drug products.
Materials and Methods
Materials and Equipment
The following materials have been employed: Kinetic-
QCL (Lonza, USA) with a sensitivity range of 0.005 
EU/ml - 50.0 EU/ml; The Kinetic-QCL™ Kinetic 
Chromogenic LAL assay is the most sensitive of the 
LAL assays and is able to quantify the concentration 
of endotoxin over a wider range and includes Kinetic-
QCL™ reagent, K50-643, Control Standard Endotoxin, 
E. coli O55:B5 endotoxin, E50-643, LAL Reagent Water, 
W50-640. Magnesium chloride hexahydrate (Merck, 
Germany), heparin injection 10000 IU/ml (Darou 
Pakhsh Pharmaceutical Company, Iran), Microplate 
Reader- SPECTROstar Nano and MARS data analysis 
software V3.01 R2 (BMG, Germany). Endotoxin-free 
glass dilution tubes (13 mm×100 mm) depyrogenated 
by heating at 250ºC for 30 min, Socorex micropipettes 
Acura825 with sterile, pyrogen-free individually wrapped 
tips, Eppendorf research plus multichannel, sterile, flat-
bottom non-pyrogenic polystyrene 96-well microplates
Preparation of LAL reagent and CSE
The LAL reagent and Control Standard Endotoxin 
(CSE) were prepared by reconstituting the lyophilized 
vials according to the instructions contained in the 
Lonza manual. When conducting the test, five serial 
dilutions of the CSE, starting from 50 EU/ml, were 
prepared using water for BET as diluent to obtain final 
endotoxin concentrations of 0.005, 0.050, 0.5 and 5 EU/
ml  (European Directorate for the Quality of Medicines, 
2013). 
Sample preparation
Samples (sample ID HS-01, HS-02 and HS-03) were 
selected randomly from three batches of heparin 10000 
IU/ml injection.  Each sample was diluted with water 
BET to give a solution containing 1000 IU of heparin 
activity per ml (solution A). The endotoxin limit 
concentration of solution A should be less than 10 IU of 
endotoxin per ml. Then serial dilutions of solution A were 
prepared according to the maximum valid dilution (MVD) 
from 1:250 to 1:2000 by dilution factors of 2 (European 
Directorate for the Quality of Medicines, 2013).
Determination of the MVD
The greatest dilution at which endotoxin limit can be 
detected is the MVD (Dawson, 1995). The MVD was 
determined for solution A by dividing the endotoxin 
limit concentration of solution A (ERL) to the lowest 
endotoxin concentration used for plotting the standard 






Solution A’s were fortified with standard endotoxin (CSE) 
to concentration of 10 EU/ml. Then serial dilution of 
spiked solution A’s were prepared in a similar way to the 
sample dilution (European Directorate for the Quality of 
Medicines, 2013).
Diluents
LAL reagent water was used as diluent in trials. 
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Magnesium chloride solution (with concentration of 5, 10 
and 25 mM) in LAL reagent water was used as diluent in 
the tests after finding the inhibitory effect. These diluents 
were used as blank in each relative test. 
Principle of the method
In the kinetic chromogenic LAL assay, a sample is mixed 
with the LAL substrate reagent, placed in an incubating 
plate reader at 37±1ºC, and the absorbance at 405 nm of 
each well of the microplate is automatically monitored, 
using the initial absorbance reading of each well as its 
own blank. The reader determines the time required for the 
absorbance to appearance of yellow color and increases 
0.200 absorbance units. This time is termed reaction 
time which is inversely proportional to the amount of 
endotoxin present. The concentration of endotoxin in 
unknown samples can be calculated from a standard curve 
(Lonza, 2012b; European Directorate for the Quality of 
Medicines, 2013). 
Preliminary evaluation of the inhibitory effect of the 
heparin with LAL assay
To evaluate the potential interference of heparin injection 
with the LAL coagulation reaction, BET was performed 
using LAL reagent water as diluent to obtain the MVD. 
Three batches of heparin injection were tested in 
triplicate, at dilutions of 1:250, 1:500, 1:1000 and 1:2000, 
corresponding to the MVD, along with the negative 
control, in triplicate. To assess the inhibitory effect, the 
spiked sample solution containing 10 EU/ml of CSE 
was also tested in triplicate. The recovery of endotoxin 
added to spike the sample solution was calculated using 
the standard curve. The acceptable spike recovery must 
be between 50-200% (European Directorate for the 
Quality of Medicines, 2013; United States Pharmacopeial 
Convention, 2014; United States Pharmacopeial 
Convention, 2014). To increase the reactivity of the LAL 
reagents and overcome the inhibitory effect of the product, 
5, 10 and 25 mM magnesium chloride solutions were used 
as diluents in triplicate in three different tests. The results 
of the preliminary evaluation allowed us to determine the 
optimal concentration of magnesium chloride in which 
LAL assay could work for heparin injection without 
any interference and increase the recovery of endotoxin 
(Lonza, 2012c).
Statistical tests
The effect of the three concentrations of magnesium 
chloride on elimination of the interference of heparin 
sodium was statistically investigated. Statistical tests 
were performed with GraphPad Prism 6.01 software 
(GraphPad software, La Jolla, USA). Data were analyzed 
using one-way ANOVA followed by Tukey’s post hoc. 
Differences with P values of <0.05 were regarded as 
significant. 
Method Validation Study
Following finding the optimum concentration of 
magnesium chloride solution, which minimized heparin 
sodium interference in the LAL assay, the aforementioned 
parameters were evaluated to validate the method.
Initial Qualification assay
The initial qualification assay was performed as a log/log 
linear correlation of the individual reaction time values 
for each replicate of standard endotoxins. The standard 
curve was prepared by plotting the log of the individual 
reaction time value (in second) for each replicate against 
the log of endotoxin concentration. Five concentrations 
of CSE in triplicate (0.005, 0.05, 0.5, 5.0 and 50 EU/
mL) were applied to determine the slope, y-intercept and 
correlation coefficient (Fernando et al., 2013).
Linearity
The linearity of three batches of heparin injection 
at dilution of 1:500 and LAL reagent water as blank 
were tested in triplicate for evaluation of linearity. The 
acceptable value of the correlation coefficient (r) must be 
≥0.980 (Fernando et al., 2013). 
Selectivity
Selectivity analysis was employed to demonstrate the 
ability of the bio-analytical method to quantify and 
differentiate the endotoxin from the components that 
might be present in the product, including metabolites, 
impurities, degradation compounds and matrix 
components (Fernando et al., 2013). 
Three batches of heparin injection at dilution of 1:500 
were tested in triplicate for evaluation of selectivity. The 
spiked recovery sample was tested in comparison with 
the non-contaminated product using the appropriate 
concentration of magnesium chloride solution obtained 
from section 2.8. . The acceptable spiked recovery must 
be between 50-200%.
Repeatability
The LAL test will meet the acceptance criteria for 
repeatability when the spike recovery value for three 
batches of heparin injection in 1:500 dilution and in 
triplicate is between 5 EU/ml and 20 EU/ml with CV of 
less than 10 percent (Rustichelli et al., 2013). 
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Results and Discussion
Preliminary evaluation of the inhibitory effect of heparin 
with LAL assay:
The results of preliminary investigation of the inhibitory 
effect of heparin, using water as diluent, were evaluated 
and are shown in Tables 1 and 2. As seen in Tables 1 and 
2, the LAL assay was performed on heparin injection 
and heparin injection spiked with 10 EU/mL of CSE in 
triplicate, at dilutions of 1:250, 1:500, 1:1000 and 1:2000, 
corresponding to the MVD, along with the negative 
control, in triplicate using LAL reagent water as diluent to 
evaluate the recovery of endotoxin. The obtained results 
indicate an inhibitory effect of heparin injection on the 
Sample Sample ID Dilution Endotoxin concentration (EU/ml)
Water for BET Direct N.D


















 N.D: Not detected
 Y-Intercept: 3.11,    Slope: -0.26,
 Correlation coefficient: 0.995, Coefficient of variation: <10%
Table 1. Determination of endotoxin in heparin injection using LAL reagent water as diluent.
Table 2. Recovery of endotoxin in spiked heparin injection using LAL reagent water as diluent.
Sample Sample ID Dilution Coefficient of variation (%)





and 10 EU/ml of 
endotoxin
HS-01
1/250 1.41 3.4 34%
1/500 4.32 4.3 43%
1/1000 4.97 2.1 21%
1/2000 6.38 3.2 32%
HS-02




1/500 3.74 4.3 43%
1/1000 3.74 2.5 25%
1/2000 2.82 2.7 27%
HS-03
1/250 2.16 3.0 30%
1/500 4.55 4.3 43%
1/1000 6.16 1.7 17%
1/2000 6.48 3.0 30%
 Y-Intercept: 3.11, Slope: -0.26,
 Correlation coefficient: 0.995, Coefficient of variation: <10%
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LAL assay since the recovery of spiked endotoxin was 
less than 50 percent in all concentrations which is not 
in compliance with the acceptance criteria (50-200%) 
recommended by the regulatory guidelines. 
In order to overcome this issue, magnesium chloride 
solution at concentrations of 5, 10 and 25 mM was used 
as diluent to provide divalent cations required by the LAL 
reaction. The results of adding magnesium chloride are 
summarized in Tables 3 to 8. They confirmed the suitability 
of magnesium chloride for reduction of inhibitory effect 
of heparin in the LAL test because endotoxin recovery 
was increased to acceptable levels (>50%) at 5, 10, 25 
Table 3. Determination of endotoxin in heparin injection using 5 mM MgCl2 solution as diluent.






















 Y-Intercept: 3.09, Slope: -0.25
  Correlation coefficient: 0.991, Coefficient of variation: <10%







10 EU/ml of 
endotoxin
HS-01
1/250 0.82 5.0 50%
1/500 2.16 5.0 50%
1/1000 3.74 5.55 55%
1/2000 4.32 5.58 56%
HS-02




1/500 2.94 5.14 51%
1/1000 3.27 5.68 57%
1/2000 4.97 6.23 62%
HS-03
1/250 1.41 5.21 52%
1/500 2.16 5.08 51%
1/1000 3.74 5.57 56%
1/2000 3.56 5.90 59%
 Y-Intercept: 3.09, Slope: -0.25
 Correlation coefficient: 0.991, Coefficient of variation: <10%
Table 4. Recovery of endotoxin in spiked heparin injection using 5 mM MgCl2 solution as diluent.
R. Solaimanian, et al. / TPPS 2016 1(2)  73-82
78
mM magnesium chloride. In order to find the optimal 
concentration of magnesium chloride the obtained values 
of endotoxin recovery were compared using one-way 
analysis of variance (ANOVA) followed by Tukey’s post 
hoc. The statistical analysis showed that the maximum 
recovery of endotoxin was obtained with magnesium 
chloride concentration of 10 mM. So, 10 mM magnesium 
Sample Sample ID Dilution Endotoxin concentration(EU/ml)
 10 mM MgCl2
 < 0.005 EU/ml
- Direct 0.001
 Heparin injection

















Y-Intercept: 3.13 Slope: -0.27
Correlation coefficient: 0.993, Coefficient of variation: <10%
Table 5. Determination of endotoxin in heparin injection using 10 mM MgCl2 solution as diluent.
chloride was considered as optimal concentration for 
LAL chromogenic test method validation.  
Validation study
Initial qualification assay
The results of the initial qualification assay are presented 
Sample Sample ID Dilution Coefficient of variation (%)





and 10 EU/ml of 
endotoxin
HS-01
1/250 0.82 6.3 63%
1/500 1.41 6.9 69%
1/1000 2.94 6.0 60%
1/2000 4.24 5.9 59%
HS-02




1/500 1.41 6.7 67%
1/1000 1.63 6.2 62%
1/2000 4.32 6.0 60%
HS-03
1/250 0.82 6.0 60%
1/500 2.16 6.8 68%
1/1000 2.16 6.1 61%
1/2000 4.08 6.1 61%
 Y-Intercept: 3.13 Slope: -0.27
 Correlation coefficient: 0.993, Coefficient of variation: <10%
Table 6. Recovery of endotoxin in spiked heparin injection using 10 mM MgCl2 as diluent.
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 Y-Intercept: 3.1, Slope: -0.24
 Correlation coefficient: 0.998, Coefficient of variation: <10%
Table 7. Determination of endotoxin in heparin injection using 25 mM MgCl2 solution as diluent.
Sample Sample ID Dilution Coefficient of variation (%)
Recovery of  
endotoxin (EU/ml) Recovery (%)
Heparin injection 
and 10 EU/ml of 
endotoxin
HS-01
1/250 0.82 5.1 51%
1/500 2.16 6.5 65%
1/1000 2.94 6.2 62%
1/2000 3.27 5.9 59%
HS-02




1/500 1.63 6.8 68%
1/1000 5.72 6.3 63%
1/2000 3.56 6.0 60%
HS-03
1/250 1.63 5.1 51%
1/500 2.94 6.6 66%
1/1000 2.94 6.4 64%
1/2000 6.68 6.2 62%
Y-Intercept: 3.1, Slope: -0.24
 Correlation coefficient: 0.998, Coefficient of variation: <10% 
Table 8. Recovery of endotoxin in spiked heparin injection using 25 mM MgCl2 solution as diluent.
in Table 9. As can be seen, the coefficient of variation 
of the reaction times for the replicates was less than 
10%. Meanwhile the slope and Y-intercept and 
correlation coefficient were -0.24, 3.08 and 0.997, 
respectively, which meet the relative acceptance criteria 
in FDA guideline on validation of the LAL test (Fernando 
et al., 2013).  
Linearity
Table 10 shows the results of the test for linearity which 
were obtained by triplicate testing of three batches of 
heparin injection spiked with 10 IU/ml of endotoxin. The 
obtained values are in compliance with the acceptable 
criteria for Coefficient of variation and percentage of 
R. Solaimanian, et al. / TPPS 2016 1(2)  73-82
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 Standard endotoxin 
 (EU/ml)
Coefficient of variation 







 Y-Intercept: (2.500 to 3.500),   Slope: (-0.40 to -0.10),
Correlation coefficient: r ≥ 0.98,   Coefficient of variation: <10% 
Table 9. Validation study of the kinetic-QCL LAL assay for heparin injection: Initial qualification assay.









HS-02+ 10 EU/ml 
endotoxin 67% 7.0 1.41
HS-03+ 10 EU/ml 
endotoxin 68% 7.11 2.16
Blank 
(10 mM MgCl2)
Direct - 0.001 0.82
 Recovered endotoxin (50-200%),     
 Coefficient of variation: (<10%)
endotoxin recovery suggested in the regulatory guidelines 
(Rustichelli et al., 2013).   
Test of selectivity
The results of the test for selectivity analysis in three 
batches of heparin injection are summarized in Table 11. 
According to the obtained results, there was no reaction 
between blanks and LAL reagent, confirming that the 
kinetic chromogenic assay detects only endotoxin.The 
spiked recovery sample was tested in comparison with 
the non-contaminated product using the appropriate 
concentration of magnesium chloride solution obtained 
from section 2.8.
Repeatability
As shown in Table 12, the CV% of the reaction times 
obtained for the triplicate tests of three batches of heparin 
injection  were <10% which is in compliance with the 
regulatory requirements (Rustichelli et al., 2013). In 
comparison with the pyrogen test using rabbits, BET is 
a highly sensitive and simple method for detection of 
endotoxins. BET is a regulatory requirement for quality 
control of injections and medical devices (European 
Directorate for the Quality of Medicines, 2013). All 
assays, independent of methodology are standardized 
using endotoxin in water. Therefore unless the sample 
is water, some substances or components of the solution 
may interfere with the LAL test even when sample 
solutions are diluted up to the MVD (Dawson, 1995; Yuu 
et al., 2011). The major interference mechanisms to be 
expected when testing various parenteral drugs for BET 
using the LAL test include: suboptimal pH conditions, 
aggregation or adsorption of control endotoxin spikes, 
unsuitable cation concentrations, enzyme or protein 
modification, nonspecific LAL activation and endotoxin 
masking (Williams, 2007). Materials such as heparin can 
bind divalent cations and reduce the aggregation state of 
endotoxin which may lead to interfere with LAL assay 
(Lonza, 2012c). In the present study we investigated the 
inhibitory effects of heparin by analyzing three batches 
of heparin injection available on the Iranian market. 
Furthermore, the suitability of kinetic chromogenic 
LAL assay for determination of endotoxin levels was 
evaluated. Since the Kinetic-QCL assay is less affected by 
inhibitory products which may interfere with the clotting 
mechanism of turbidimetric and gel clot assays, so, in the 
case of heparin injection, Kinetic-QCL assay could be the 
method of choice (Lonza, 2012b). 
Table 10. Validation study of the kinetic-QCL LAL assay for heparin injection: Linearity.
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Table 11. Validation study of the kinetic-QCL LAL assay for heparin injection: Selectivity.








HS-02 - 0.3 5.73
HS-03 - 0.31 6.70
HS-01+ 10 EU/ml 
endotoxin 69% 7.16 1.41
HS-02+ 10 EU/ml 
endotoxin 67% 7.0 1.41
HS-03+ 10 EU/ml 
endotoxin 68% 7.11 2.16
Blank Direct - 0.001 0.82
 Coefficient of variation: <10%
Table 12. Validation study of the kinetic-QCL LAL assay for heparin injection: Repeatability.
Sample Dilution Coefficient of variation(<10%)













The results obtained confirmed the inhibitory effect 
of heparin injection with routine LAL assay because the 
recovery of spiked endotoxin was less than 50 percent. On 
the other hand, simple dilution, even up to the MVD could 
not overcome the interference properties of heparin. Since 
non-inhibitory dilution was not found even at MVD, to 
determine suitable level of a divalent cation that would 
inhibit heparin interference, magnesium chloride solution 
at concentrations of 5, 10 and 25 mM was used as a diluent. 
The acceptable range of recovery (>50%) was observed 
with all concentrations of magnesium chloride. Hence, 
to find the optimal concentration of magnesium chloride 
solution, the effect of the aforementioned magnesium 
chloride concentrations on the elimination of interference 
was compared using ANOVA statistical method. 
The results of ANOVA revealed that for the dilution 
of 1:250, 1:500 and 1:1000 of heparin 1000 IU/ml 
injection, magnesium chloride at concentration of 10 mM 
showed significantly better effects on overcoming LAL 
interference. 
Therefore, for the above dilutions of heparin, 10 
mM magnesium chloride was found as the optimal 
concentration for providing suitable level of divalent 
cations required for the LAL assay.  As heparin is a 
chelating agent it can reduce the aggregation state of 
endotoxins due to binding of divalent cations. This 
results in increased reactivity, which is observed as 
enhancement. In contrast, sequestration of cations 
makes them unavailable for optimum enzyme activity 
of LAL cascade resulting inhibition (Dawson, 2005).
According to the ANOVA results for dilution of 1:2000, 
5 mM magnesium chloride showed significant effects on 
endotoxin recovery. Decreased concentration of heparin 
at 1:2000 dilution is led to less binding of divalent cations. 
So, lower concentration of magnesium chloride (5 mM) 
was needed to eliminate the inhibitory effects.
The obtained results show that providing adequate 
quantities of the divalent cations such as magnesium salts 
can decrease the inhibitory effect of heparin in the LAL 
assay.
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Conclusion
It was found that a 10 mM magnesium chloride solution, 
as diluent, produced the optimum recovery of endotoxins 
from Heparin injection. Based on this finding, a method 
validation of the Kinetic-QCL assay for determination of 
endotoxin level of heparin injection was performed. By 
evaluating method qualification, selectivity, linearity and 
repeatability, the endotoxin chromogenic method was 
validated in accordance with European/US Pharmacopeia. 
Therefore, this method is suitable as a release test for 
determination of bacterial endotoxin levels in heparin 
injection (Food and Drug Administration, 1992; European 
Directorate for the Quality of Medicines, 2013; United 
States Pharmacopeial Convention, 2014). 
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